Geron shares are trading higher after the company submitted FDA application for imetelstat for transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes.
Portfolio Pulse from Benzinga Newsdesk
Geron's stock is trading higher after submitting an FDA application for imetelstat, a treatment for transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes.
June 20, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron's stock price is likely to increase in the short term due to the submission of the FDA application for imetelstat.
The submission of the FDA application for imetelstat is a significant milestone for Geron, as it indicates progress in the development of the drug. This news is likely to be viewed positively by investors, leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100